iStar Medical announces positive 3-year results from STAR-GLOBAL trial


The trial is for the MINIject MIGS device for patients with primary open-angle glaucoma.

(Image Credit: AdobeStock/Lucky Ai)

(Image Credit: AdobeStock/Lucky Ai)

iStar Medical has announced positive 3-year results from the STAR-GLOBAL trial for the MINIject® in open-angle glaucoma patients.

According to a press release from iStar, the STAR-GLOBAL trial is an extension trial investigating the long-term safety and efficacy of patients up to 5-years of follow-up.1

MINIject® is iStar Medical’s innovative MIGS device for patients with primary open-angle glaucoma. According to iStar, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications.1

iStar reported the interim data from 48 patients in the STAR-GLOBAL trial who completed 3-year follow-up during the iStar Medical symposium at the World Glaucoma Congress (WGC) in Rome, Italy.

The efficacy results indicate a sustained, meaningful 36% reduction of eye pressure at 3 years with 42% of patients being medication-free, according to data from the press release. A favorable safety profile including corneal health was confirmed at 3-year follow-up, with no serious adverse events related to the device or procedure in the STAR-GLOBAL follow-up period.1

Inder Paul Singh, MD, MPH, glaucoma specialist and president of the Eye Centers of Racine & Kenosha said about the results, “The safety and efficacy observed at up to three-year follow-up is highly encouraging as it demonstrates the sustained and meaningful performance of iSTAR Medical’s MINIject® into the longer term. This confirms the consistent safety and efficacy profile MINIject has already shown in previous STAR trials.”

In the press release, the CEO of iStar Michel Vanbrabant talked about the trial saying; “These data from our ongoing STAR-GLOBAL trial further validate MINIject’s safety and efficacy as a supraciliary MIGS implant to reduce eye pressure in open-angle glaucoma patients. These positive STAR-GLOBAL follow-up data strengthen the evidence for MINIject® as a safe, standalone procedure and a promising treatment option for glaucoma patients in the longer-term, meaning patients can be assured that MINIject® remains safe and effective several years after surgery.”

  1. iSTAR Medical presents positive three-year results for MINIject® from STAR-GLOBAL trial. Press Release. Released September 7, 2023. Accessed September 7, 2023.
Recent Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
© 2024 MJH Life Sciences

All rights reserved.